## RECEIVED CENTRAL FAX CENTER

MAR 3 0 2007

# Facsimile Cover Sheet For Transmission to the United States Patent and Trademark Office

o:	U.S. Patent and Trademark Office							
	Fax. No. (571) 273-8300							
	Application No.	10/696,464 October 29, 2003 5983 Celia C. Chang 1625						
	Filing Date:							
	Confirmation No.:							
	Examiner:							
	Art Unit:							
	Attorney Docket No.	P-142-US1						
From:	Theravance, Inc.							
	Attorney:	Jeffrey A. Hagenah						
	Reg. No.:	35,175 27038						
	Customer No.:							
		901 Gateway Boulevard						
	Address:	South San Francisco, California 94080						
	Telephone No.:	(650) 808-6406						
	Fax. No.:	(650) 808-6078						
Date:	March 30, 2007	March <u>30</u> , 2007						
No. of Pages :	31 (including this pa	31 (including this page)						
	Certificate of Fa	csimile Transmission						
I hereby certify the Number (571) 27 the date indicate	hat this correspondence 73-8300 to the United Sta	is being transmitted via Facsimile ates Patent and Trademark Office, on						
Signature :	Man A	· May						
Printed Name :	Jeffrey A. Hagenah, Reg. No. 35,175							

The information contained in this facsimile is intended solely for use by the United States Patent and Trademark Office. If this facsimile is received in error, please notify the sender and destroy the facsimile.

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

	<del></del>	Application Number	11	0/696,464	7	<b>*********</b>	
TRANSMITTA	Filing Date	0	ctober 29, 2	RECEIVED ENTRAL FAX CENTE			
FORM	First Named Inventor	N	Mammen et al.		SHIPAL PAX CENTE		
		Art Unit	1	625		MAR <b>3 0</b> 2007	
	Examiner Name	C	elia C. Cha	ng			
(to be used for all correspondence after Total Number of Pages in This Submis	Attorney Docket Numb	oer F	2-142-US1				
Total Number of Pages in The Sassin		OSURES (check all that ap					
			<u>,,,,,,</u>	After Allow	ance Communication to TC		
Fee Transmittal Form		Drawing(s)		Appeal Communication to Board			
Fee Attached Licensi		g-related Papers		of Appeals and Interferences  Appeal Communication to TC		·	
Amendment / Reply (29 pages)	Petition	Petition			ice, Brief, Reply Brief)		
After Final	Provision	Petition to Convert to a Provisional Application			Information		
Affidavits/declaration(s)	Power o Change	Power of Attorney, Revocation Change of Correspondence Address			ter		
Extension of Time Request	Termina	Terminal Disclaimer		Other Enclosure(s) (please identify below):			
	Request for Refund			Facsimile Cov	er Page (1 page)		
Express Abandonment Request	CD, Nur	CD, Number of CD(s)					
Information Disclosure Statemen	.	andscape Table on CD				4	
Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application	Remarks No fees are	are believed to be due for submission of this paper. However, if a fee is due, amissioner is authorized to charge any such fee, or to credit any ment, to Deposit Account No. 50-0344 (in the name of Theravance, Inc.)					
Reply to Missing Parts under 37 CFR1.52 or 1.53							
S	GNATURE O	F APPLICANT, ATTORN	VEY, OR	AGENT	· · · · · · · · · · · · · · · · · · ·	4	
		ance, Inc.					
Signature		AAA					
Printed Name (leffre)		. Hagenah					
Date March 3		, 2007	Reg. No.	35,175			
	CERTIFI	CATE OF TRANSMISSI	ON/MAI	LING	with the United States Posts	<del></del>	
I hereby certify that this correspon Service with sufficient postage at Alexandria, VA 22313-1450 on the	3 IIISI WASS 1116	all lif all citionape addition	USPTO	or deposited commissioner	for Patents, P.O. Box 1450	ó; 	
Signature	2/2	AW				<b>-</b>	
Typed or printed name Jeffre	y Hogenah, I	Reg. No. 35,175		Date	March 30, 2007	<u> </u>	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete in not under the complete state of the

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

MAR 3 0 2007

## Certificate of Facsimile Transmission

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to the Commissioner for Patents, United States Patent and Trademark Office at the facsimile number indicated.

Dated: March 30, 2007 Facsimile Number: (571) 273-8300

By: Jeffing A. Hagenah, Reg. No. 3, 175

PATENT Attorney Docket No. P-142-US1 Customer No. 27038

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
In re Patent Application of

MAMMEN et al.

Application No.: 10/696,464

Filed: October 29, 2003

For: SUBSTITUTED 4-AMINO-1
(PYRIDYLMETHYL)PIPERIDINE

AND RELATED COMPOUNDS

To the patent And TRADEMARK OFFICE

Confirmation No. 5983

Confirmation No. 5983

Examiner: Celia C. Chang

AND TRADEMARK OFFICE

Confirmation No. 5983

Examiner: Celia C. Chang

Office Confirmation No. 5983

Application No. 10/696,464

AND RELATED COMPOUNDS

## REPLY AND AMENDMENT PURSUANT TO 37 C.F.R. §1.111

#### Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

### I. INTRODUCTORY REMARKS

This reply is being filed in response to the Office Action mailed on January 23, 2007, for the above-identified patent application. The Office Action set a three-month period for response and therefore, this reply is due on or before April 23, 2007. In response to the Office Action, entry of the following amendments and consideration of the following remarks is respectfully requested.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 27 of this paper.